Literature DB >> 7332382

Prolonged reduction in polymorphonuclear adhesion following oral colchicine.

J N Fordham, J Kirwan, J Cason, H L Currey.   

Abstract

Polymorphonuclear leucocyte (PMN) function was studied in 7 healthy subjects before and after 5 mg of colchicine taken in divided doses over 24 hours. Mean adherence to nylon fibre colums fell from a pretreatment level of 51% to 33.6% by day 1, remained low (31.8%) at day 5, and returned to pretreatment levels only by about day 9. Random motility (agarose plate method) fell from 932 micrometers to 688 micrometers by day 1, but had returned to normal by day 5. Directed migration and the phagocytic index (opsonised Candida albicans method) were not affected by colchicine treatment. In this marked and prolonged reduction in PMN adhesion implies an influence on maturing PMN precursors in bone marrow. Adherence to nylon fibres may reflect in-vivo properties of PMN which are important in the pathogenesis of acute gouty arthritis.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7332382      PMCID: PMC1000839          DOI: 10.1136/ard.40.6.605

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

1.  The effect of anti-inflammatory agents and inflammation on granulocyte adherence. Evidence for regulation by plasma factors.

Authors:  R R MacGregor
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

2.  Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylate.

Authors:  D G Wright; S E Malawista
Journal:  Arthritis Rheum       Date:  1973 Nov-Dec

3.  Colchicine plasma levels. Implications as to pharmacology and mechanism of action.

Authors:  S L Wallace; B Omokoku; N H Ertel
Journal:  Am J Med       Date:  1970-04       Impact factor: 4.965

4.  The inflammatory reaction to microcrystalline sodium urate.

Authors:  D J McCarty
Journal:  Arthritis Rheum       Date:  1965-10

5.  Leukocyte migration agarose test for the assessment of human neutrophil chemotaxis. I. Effects of environmental factors on neutrophil migration under agarose.

Authors:  H Repo
Journal:  Scand J Immunol       Date:  1977       Impact factor: 3.487

6.  Studies on neutrophil function. 1. Physiological and pharmacological aspects.

Authors:  R Penny; D A Galton; J T Scott; V Eisen
Journal:  Br J Haematol       Date:  1966-09       Impact factor: 6.998

7.  Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever.

Authors:  C A Dinarello; M J Chusid; A S Fauci; J I Gallin; D C Dale; S M Wolff
Journal:  Arthritis Rheum       Date:  1976 May-Jun

8.  Neutrophil kinetics in man.

Authors:  J T Dancey; K A Deubelbeiss; L A Harker; C A Finch
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

9.  Urate crystal-induced chemotactic factor: isolation and partial characterization.

Authors:  I Spilbert; A Gallacher; J M Mehta; B Mandell
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

10.  Interaction of Candida albicans with human leukocytes and serum.

Authors:  R I Lehrer; M J Cline
Journal:  J Bacteriol       Date:  1969-06       Impact factor: 3.490

View more
  9 in total

Review 1.  Update on colchicine and its mechanism of action.

Authors:  Yair Molad
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

2.  Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation.

Authors:  Jui-Hsia Weng; Peter David Koch; Harding Luan; Ho-Chou Tu; Kenichi Shimada; Iris Ngan; Richard Ventura; Ruomu Jiang; Timothy J Mitchison
Journal:  Nat Metab       Date:  2021-04-12

Review 3.  Colchicine--Update on mechanisms of action and therapeutic uses.

Authors:  Ying Ying Leung; Laura Li Yao Hui; Virginia B Kraus
Journal:  Semin Arthritis Rheum       Date:  2015-06-26       Impact factor: 5.532

4.  Pharmacological modification of 12-0-tetradecanoylphorbol-13-acetate induced inflammation and epidermal cell proliferation in mouse skin.

Authors:  R J Griffiths; B E Wood; S Li; A Blackham
Journal:  Agents Actions       Date:  1988-12

5.  In silico study of colchicine resistance molecular mechanisms caused by tubulin structural polymorphism.

Authors:  Harutyun Sahakyan; Narek Abelyan; Vahram Arakelov; Grigor Arakelov; Karen Nazaryan
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

6.  The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials.

Authors:  Chia Siang Kow; Learn-Han Lee; Dinesh Sangarran Ramachandram; Syed Shahzad Hasan; Long Chiau Ming; Hui Poh Goh
Journal:  Immun Inflamm Dis       Date:  2021-12-30

Review 7.  Immunomodulatory drug discovery from herbal medicines: Insights from organ-specific activity and xenobiotic defenses.

Authors:  Jue Shi; Jui-Hsia Weng; Timothy J Mitchison
Journal:  Elife       Date:  2021-11-15       Impact factor: 8.140

8.  Adding colchicine to tocilizumab in hospitalized patients with severe COVID-19 pneumonia: An open-label randomized controlled trial.

Authors:  Alaa Rahhal; Mostafa Najim; Amer Hussein Aljundi; Ahmed Mahfouz; Sumaya Mehdar Alyafei; Ahmed Awaisu; Mhd Baraa Habib; Ibrahim Obeidat; Mohanad Mohammed Faisal; Meshaal Ali Alanzi; Arun Prabhakaran Nair; Areeg Elhassan; Abdullah Al-Dushain; Alaaeldin Abdelmajid Abdelmajid; Ahmed Elfadil Abdelgader; Ahmed Mahmoud Ahmed Moursi; Ahmad Eid Nazzal Alharafsheh; Mohd Ragheb Abou Kamar; Wael Goravey; Amr Salah Omar; Mohammed Abukhattab; Mohamad Yahya Khatib; Mohamed Gaafar Mohamedali; Muna A Rahman AlMaslamani; Samar Alemadi
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

Review 9.  Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation.

Authors:  Aldo Bonaventura; Alessandra Vecchié; Lorenzo Dagna; Flavio Tangianu; Antonio Abbate; Francesco Dentali
Journal:  Inflamm Res       Date:  2022-02-03       Impact factor: 4.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.